Highlights from the 17th BGICC: Day 1 of Breast-Gynecological International Cancer Conference
Breast Gynecological and Immunooncology International Cancer Conference (BGICC) 2025 is taking place on January 23-24, 2025, at the Hilton Cairo Heliopolis.
With 5,000 participants from over 50 countries, BGICC has grown to become a global hub for knowledge-sharing and collaboration in cancer care. Founded to advance research in breast and gynecological oncology, the conference provides an unparalleled opportunity for specialists to exchange ideas, discuss cutting-edge research, and shape the future of oncology.
BGICC 2025 is more than a conference – it is a movement towards global innovation and collaboration in oncology. With esteemed speakers, groundbreaking research, and attendees from around the world, the event promises to deliver meaningful outcomes that will shape the future of cancer care.
The BGICC 2025 brought together an exceptional panel of keynote speakers who illuminated the global stage with groundbreaking insights and transformative discussions in breast cancer care.
Prof. Giuseppe Curigliano, President-Elect of ESMO, presented groundbreaking results from the DESTINY-Breast06 trial. He showcased the efficacy of trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer (mBC), offering hope for improved outcomes in these challenging cases.
Prof. Joseph Gligorov passionately advocated for the universal first-line use of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer patients. Highlighting substantial improvements in progression-free and overall survival, he emphasized their favorable safety profile and broad efficacy across diverse patient subgroups. While addressing challenges such as cost and patient selection, Prof. Gligorov underscored the transformative potential of CDK4/6 inhibitors and urged global efforts to improve access to this life-changing therapy.
Prof. Hope Rugo delivered critical insights into the treatment of early-stage triple-negative breast cancer (T1c node-negative), affirming that chemotherapy remains the standard of care. She pointed to high survival rates, manageable long-term risks, and the limited benefit of immunotherapy in this low-risk group. Prof. Rugo stressed the importance of smarter, biology-driven treatment strategies rather than routine escalation with immune checkpoint inhibitors. She also shared updates on the evolving therapeutic landscape for metastatic HER2+ breast cancer, enriching the dialogue on optimizing patient outcomes.
In a compelling debate, Prof. Matti Aapro presented a nuanced perspective against the universal first-line use of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer. Drawing on evidence from the SONIA trial, he argued that delaying CDK4/6 inhibitors in certain subgroups does not compromise outcomes and proposed a more selective approach. He advocated prioritizing high-risk patients for first-line CDK4/6 inhibitors while considering endocrine therapy alone for lower-risk cases, balancing cost-effectiveness, toxicity, and patient-centered care. As Prof. Aapro noted,
“CDK4/6 inhibitors have transformed care, but universal use isn’t always needed. A tailored approach ensures better outcomes and sustainability.”
Dr. Julie Gralow explored the management of pT1c triple-negative breast cancer (TNBC) and the potential role of immune checkpoint inhibitors (ICIs) in early-stage disease. She emphasized that while immunotherapy holds promise for early-stage TNBC, questions remain about its role in specific subgroups like T1cN0. Dr. Gralow called for further studies to refine patient selection, optimize treatment combinations, and reduce toxicity, paving the way for more personalized approaches.
Dr. Hesham El-Ghazaly highlighted Egypt’s strides in breast cancer care through innovative and collaborative efforts. He showcased the development of evidence-based, cost-effective care models designed to improve accessibility. His presentation demonstrated how Egypt’s presidential initiative has addressed gaps in healthcare delivery, positioning the nation as a global model for addressing inequities in cancer care.
Prof. Fabrice André, ESMO President, delivered a thought-provoking keynote on the potential of immunotherapy in luminal breast cancer. He acknowledged the current limited benefits of immunotherapy in this subtype but emphasized ongoing research into biomarkers, combination strategies, and innovative approaches that could redefine its role. Prof. André underscored the importance of collaboration between research and clinical practice to address the complexities of luminal breast cancer and unlock the broader potential of immunotherapy.
The BGICC 2025 keynote sessions provided a wealth of knowledge, pushing the boundaries of breast cancer research and care while fostering a spirit of global collaboration and innovation.
Not to miss highlights from BGICC 2025 picked by OncoDaily:
“Capturing Every Moment at BGICC 2025!
Day 1 of the 17th Breast Gynecological and Immunooncology International Cancer Conference (BGICC) is in full swing, and our cameras are rolling to bring you the highlights of this incredible event!
From inspiring keynote speeches to groundbreaking sessions and vibrant networking moments, we’re documenting it all. Stay tuned for daily updates, behind-the-scenes glimpses, and snapshots of the brightest minds in oncology from around the globe.
Date: 23 January 2025
Venue: Hilton Cairo Heliopolis
Let’s celebrate innovation, collaboration, and progress in the fight against cancer—one shot at a time.”
Ministry of Health and Population – Egypt:
“During his speech at the opening session of the 17th Breast-Gynecological International Cancer Conference.
Deputy Prime Minister and Minister of Health: The Political Leadership Pays Great Attention to the Health File and Patients with Breast Cancer Tumors.
Conference President stresses its importance in providing important scientific discussions on immunotherapies and tumor destructive therapies.”
“BGICC 2025 kicked off with 5000 attendees in Cairo, Egypt! Prof. Giuseppe Curigliano set the stage with an inspiring session on DESTINY-Breast06, highlighting the potential of T-DXd in HER2-low/ultralow HR+ mBC.
OncoDaily is here – stay tuned for live podcasts and onsite interviews!”
“The fun starts, pathology updates from the Gurus. Michigan university- Pathology.”
Egyptian Society of Breast Imaging – EGSBI:
“Excited to kick off the first day of BGICC 2025!
The EGSBI team is here to share knowledge, connect with experts, and highlight the latest in breast imaging. Stay tuned for updates from the conference!”
“OncoDaily is in Cairo!
The 17th BGICC has officially started with more than 5,000 participants from across the globe.
Follow OncoDaily for the latest updates and key moments from this incredible event.”
“Today, I had the privilege of attending the Cairo Breast Cancer Gynecologist & Immunoongology International Conference. This enriching experience significantly broadened my knowledge in the field, providing invaluable insights from leading experts. I was fortunate to connect with esteemed professors and doctors from around the globe, fostering valuable professional relationships. The conference served as a powerful reminder of the continuous evolution of cancer research and treatment, inspiring me to further contribute to advancements in this critical area.”
Also I want to thank these genuine people
Dr. Ashan Musafer
Field Application Scientist at Oxford Nanopore Technologies , It was outstanding presentation and very useful !Thanks a lot Dr Ashan.
Also want to thank Prof Hend El Tayebi for giving us all this information about Breast Cancer (TNBC) MDA-MB 231, Impact of MALAT-1 and HOTAIR silencing on VEGF-A protein releaso from TAMs of HER2+ & TNBC BC subtype and a lot of information that have widen my knowledge in breast cancer field ,It was very useful !
Prof . Fabio Pagni Università degli Studi di Milano-Bicocca for digital and molecular pathology, Thanks a lot prof for these incredible presentation !!!
Also want to thank every Prof and Dr was over there such an incredible day.
So glad to participate at Il Cairo Breast Gynecological & Immunooncology International Cancer Conference-BGICC
1st day.”
“Proud to Announce My Attendance at the 17th BGICC 2025!
I am delighted to share that I will be attending the Breast Gynecological and Immunooncology International Cancer Conference (BGICC 2025)—the largest and most prestigious cancer conference in Africa and the Middle East.
Where: Hilton Heliopolis Hotel, Cairo, Egypt
When: January 23rd–24th, 2025
This incredible event will feature rich content lectures, hands-on workshops, and in-depth courses focused on advancing cancer research and treatment.
Under the theme “Illumination and Creation,” BGICC 2025 is set to bring together top professionals and innovators in oncology to drive impactful change.
I’m looking forward to gaining valuable insights, building connections, and contributing to the future of cancer care.”
“I am honored to participate in BGICC WITH MY E-POSTER about Herceptin biosimilar KANJINTI in treatment of HER2 positive breast cancer.”
“I had the privilege of attending BGICC today, a pivotal conference empowering a cancer-free future, and shedding light on the latest advancements in cancer treatment.
As a proud member of MSD team, I’m committed to our mission of improving lives and making a difference in the healthcare landscape.”
“It always looks great moments to represent CCHE 57357 nursing sector in 17th BGICC.”
“Iam proud to have abstract in the 17th BGICC Oncology Conference, where our research was published in collaboration with my colleagues Ereeny raouf and Asmaa mohamed A heartfelt thank you to Dr. Mohamed Abdel Aziz for his tremendous effort, guidance, and support, which greatly contributed to this achievement.”
“I’m extremely honored and privileged to be part of this prestigious event Breast Gynecological and Immunooncology International Cancer Conference-BGICC, sharing the knowledge and updates in breast cancer diagnosis and management among oncology and pathology experts.
Don’t miss the chance to join the multidisciplinary panel discussion, sponsored by Roche Middle East, to learn more about the best practices in breast cancer management for the best to our patients.”
“I am so proud to have participated in The Breast Gynecological &Immuno-oncology International Cancer Conference(BGICC)17
Hilton Hilopilis Cairo 23/1/2025.”
“A great opportunity to be in the presence of this much talent and genius at the 17th BGICC for Breast Cancer Gynecological and Immuno-oncology International Cancer conference
All my gratitude to the speakers for their knowledge of molecular diagnosis and treatment methods for cancer.”
“I had the incredible opportunity to attend the 17th Breast Gynecological & Immunooncology International Cancer Conference-BGICC and BioNetMasr Network Masr and wanted to express my gratitude to all the speakers who shared their knowledge and insights. Grateful for the opportunity to be part of such an enriching conference and to connect with brilliant minds in the field. Let’s continue advancing our understanding and treatment of cancer through collaborative efforts!”
Egyptian Society of Breast Imaging – EGSBI:
“The first day of the BGICC Conference 2025 concluded successfully with a remarkable lineup of sessions and hands-on workshops!
Here’s a recap of Day 1:
Scientific Sessions:
• 𝐏𝐫𝐨𝐟. 𝐑𝐚𝐬𝐡𝐚 𝐊𝐚𝐦𝐚𝐥 Welcome Note
• 𝐏𝐫𝐨𝐟. 𝐉𝐞𝐬𝐬𝐢𝐜𝐚 𝐥𝐞𝐮𝐧𝐠𝐞: BI-RADS 6th Edition – What Has Changed?
• 𝐏𝐫𝐨𝐟. Jennifer Harvey: Breast Calcifications Made Easy
• 𝐏𝐫𝐨𝐟. Niketa Chotai: AI in Breast Imaging: Will It Replace the Radiologist?
• 𝐏𝐫𝐨𝐟. Tanya Chawla: Pitfalls in Gynecologic Imaging
• 𝐏𝐫𝐨𝐟. Merit Elmaadawy: Fat Necrosis or Something Else? Navigating the Challenges in Interpretation
• 𝐏𝐫𝐨𝐟. 𝐑𝐚𝐬𝐡𝐚 𝐊𝐚𝐦𝐚𝐥: Patterns of Contrast Uptake in Different Breast Pathologies
• Panel Discussion: Pregnancy-Associated Breast Cancer – Imaging Protocols and Guide to Management, moderated by 𝐏𝐫𝐨𝐟. 𝐀𝐦𝐥 𝐇𝐞𝐠𝐚𝐳𝐲
Workshops:
•Pelvic Imaging Workshop: Led by 𝐀.𝐏𝐫𝐨𝐟. 𝐇𝐞𝐛𝐚 𝐇𝐚𝐬𝐬𝐚𝐧
supported by Siemens Healthineers .
•Breast Intervention Workshop:
Led by, 𝐏𝐫𝐨𝐟. 𝐀𝐦𝐥 𝐇𝐞𝐠𝐚𝐳𝐲 , 𝐃𝐫. 𝐋𝐚𝐦𝐢𝐚𝐚 𝐀𝐝𝐞𝐥, and 𝐏𝐫𝐨𝐟. Merit Elmaadawy .
supported by Siemens Healthineers .
•Test Your Skills Against AI:
Led by Dr. Yasmin nada supported by Fujifilm Global Technology.
•Test Your Mammography and CEM Reading Skills:
Led by 𝐃𝐫.𝐒𝐡𝐞𝐫𝐢𝐡𝐚𝐧 𝐅𝐚𝐤𝐡𝐫𝐲 and 𝐃𝐫. 𝐄𝐦𝐚𝐧 𝐅𝐚𝐤𝐞𝐫
supported by GE HealthCare
We’re looking forward to more exciting sessions and interactions on Day 2!”
Stay tuned with OncoDaily for live updates, session highlights, and interviews with global leaders in oncology.
Further Reading:
Introducing the Radiology Course at BGICC 2025
BGICC 2025: Hear from Global Oncology Leaders
How Egypt is closing the gap in breast cancer care: Dr. Hesham El-Ghazaly leads the conversation
The 17th Annual BGICC Conference Kicks Off in Cairo, Egypt with 5,000 Attendees
Scientific Insights from Prof. Hope Rugo: Advancements in Metastatic HER2+ Breast Cancer Therapy
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023